Harrow Health Inc (HROW)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.13B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harrow Health Inc (HROW) Stock Forecast
Analysts expect Harrow Health (HROW) to earn $0.04 per share in the fiscal year ending Dec 31, 2026, on revenue of $348.90M. Of 9 analysts, 9 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $2.66.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 9 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 6550.0% and revenue estimates rise 56.0%.
- Fiscal year ending Dec 31, 2026
- $0.04
- EPS consensus, revenue $348.90M
- Fiscal year ending Dec 31, 2027
- $2.66
- EPS consensus, revenue $544.34M
- Next report
- Mar 1, 2027
- Confirmed, after the close
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.04 | $0.01 to $0.07 | 2 | $348.90M | $341.00M to $351.70M | 7 |
| Dec 31, 2027 | $2.66 | $2.01 to $3.10 | 3 | $544.34M | $495.26M to $576.79M | 6 |
Quarterly Estimates
The EPS consensus falls from $0.58 for the quarter ending Dec 31, 2026 to -$0.51 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.58 | $0.33 to $0.79 | 11 | $139.31M | $132.51M to $147.60M | 11 |
| Mar 31, 2027 | -$0.51 | -$0.51 to -$0.51 | 1 | $89.44M | $84.91M to $96.60M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 90.5% from $0.42.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.04 | $0.17 | $0.22 | $0.22 | $0.42 | -90.5% |
| Fiscal year ending Dec 31, 2027 | $2.66 | $2.57 | $2.77 | $2.83 | $2.56 | +4.2% |
| Quarter ending Mar 31, 2027 | -$0.51 | -$0.15 | -$0.10 | -$0.10 | -$0.10 | N/A |
Frequently Asked Questions About HROW
What is the HROW stock forecast?
Consensus analyst estimates put Harrow Health's EPS at $0.04 for the fiscal year ending Dec 31, 2026, on revenue of $348.90M. The consensus rating from 9 analysts is Buy.
How do analysts rate HROW stock?
Of 9 analysts covering Harrow Health, 0 rate it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from HROW next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.04, with estimates from $0.01 to $0.07 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.66, with estimates from $2.01 to $3.10 from 3 analysts.
What revenue do analysts expect from Harrow Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $348.90M, with estimates from $341.00M to $351.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $544.34M, with estimates from $495.26M to $576.79M.
How many analysts cover HROW?
9 analysts rate Harrow Health stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HROW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors